Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD), Vanguard Health Care ETF (VHT): How to Invest in Health Care

Sector exchange-traded funds, or ETFs, allow nervous investors to sample from the fast-paced health care industry with lessened risk. But how do you choose the best health care ETF for your portfolio?

ETFs exist for every aspect of the health care industry including medical devices and insurance companies. But the standouts focus on either a mix of drugmakers and biotechs or an all-biotech buffet.

Gilead Sciences, Inc. (NASDAQ:GILD)

Here are three sector ETFs to consider.

1. A broad bundle
Vanguard Health Care ETF (NYSEARCA:VHT)
 tracks the MSCI US IMI Health Care 25/50. The ETF contained 293 stocks as of the last quarter. Pharmaceuticals accounted for more than 40% of the holdings, with biotech coming in second with 19.4%. That’s reflected in the five largest holdings: Johnson and Johnson, Pfizer, Merck, Gilead Sciences, Inc. (NASDAQ:GILD), and Amgen.  Vanguard Health Care ETF (NYSEARCA:VHT) is up 27.74%, as of September 5 pre-market.

This ETF has a well-balanced top five. Johnson and Johnson, Pfizer, and Merck are all Dogs of the Dow , and the former two in particular have enough segments to withstand a hit here and there.

Gilead Sciences, Inc. (NASDAQ:GILD) is up more than 100% in the past year. The company stands at the forefront of the much-anticipated all-oral hepatitis C treatments and has historically led the market in HIV drugs. Amgen leads a new class of cholesterol medications that could step in where statins fail.

The ETF has an expense ratio of 0.14% and an average volume of around 170,000. Vanguard Health Care ETF (NYSEARCA:VHT) offers commission-free trading on its ETFs.

2. Large piece of biotech
 tracks the S&P Biotechnology Select Industry Index.  Holdings include 56 biotech companies with Alnylam, Incyte, and NPS Pharmaceuticals at the top. The ETF is up 42.59% year-to-date.

The ETF’s top holdings represent companies still on the brink of breaking out in a big way. Alnylam’s potential lays in its RNAi therapeutics and discovery methods, which could revolutionize the biotech industry. The company has a 5×15 program, which hopes to have five drugs in clinical development before 2015. Incyte focuses on cancer and inflammation treatments, and its stock popped last month following positive mid-stage trials for metastatic pancreatic cancer. NPS had a strong launch for its short-bowel syndrome treatment and should soon submit regulatory paperwork for a hypoparathyroidism treatment.

This biotech spider has a gross expense ratio of 0.35% and an average volume of around 305,000.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.